Correction to: Drugs & Therapy Perspectives 2018 34(10):457–465 https://doi.org/10.1007/s40267-018-0547-6
The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access. After publication in volume 34, issue 10, pages 457–465, Ipsen Pharma requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Ipsen Pharma. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The original article has been corrected.
Change history
21 February 2019
Paragraph 1, Sentences 1 and 2: the following text, which previously read:
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
OpenAccess This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Lyseng-Williamson, K.A. Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Drugs Ther Perspect 35, 100 (2019). https://doi.org/10.1007/s40267-018-00596-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-018-00596-3